Evidence map›Paper›PMID 39312297›Full record

ArticleThe Cochrane database of systematic reviews2024

Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma.

Tibor A Zwimpfer, Hannah Ewald, Esra Bilir, Madawa Jayawardana, Christian Appenzeller-Herzog, Nicolò Bizzarri, Zoia Razumova, Joanna Kacperczyk-Bartnik, Viola Heinzelmann-Schwarz, Michael Friedlander and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Cochrane database of systematic reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tibor A ZwimpferPeter MacCallum Cancer Centre, Melbourne, Australia.
Hannah EwaldUniversity Medical Library, University of Basel, Basel, Switzerland.
Esra BilirDepartment of Global Health, Koç University Graduate School of Health Sciences, Istanbul, Turkey.
Madawa JayawardanaPeter MacCallum Cancer Centre, Melbourne, Australia.
Christian Appenzeller-HerzogUniversity Medical Library, University of Basel, Basel, Switzerland.
Nicolò BizzarriUOC Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
Zoia RazumovaDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Joanna Kacperczyk-BartnikDepartment of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland.
Viola Heinzelmann-SchwarzGynaecological Cancer Centre, University Hospital Basel, Basel, Switzerland.
Michael FriedlanderMedical Oncology, Prince of Wales Hospital, Sydney, Australia.
David Dl BowtellPeter MacCallum Cancer Centre, Melbourne, Australia.
Dale W GarsedPeter MacCallum Cancer Centre, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors.

Indexed as

Ovarian NeoplasmsCystadenocarcinoma, SerousFallopian Tube NeoplasmsFemaleGenes, BRCA1Genes, BRCA2HumansMutationPrognosisProgression-Free Survival

Identifiers

PMID39312297
PMCPMC11418971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.